这是一项先导研究，旨在评估以 Doxorubicin + Cisplastin 进行 PIPAC 对胃癌腹膜转移（PM）患者的成效。所有在香港威尔斯亲王医院（PWH）确诊胃癌并伴有腹膜转移的患者均会接受资格筛查。 本研究有两个目标： 1.
适应症：Gastric Cancer Peritoneal Metastases
入组条件
纳入标准
- Patients age \>= 18, \<= 80 years old
- Performance status (WHO) \<=2
- Histologically evidenced synchronous PM of gastric adenocarcinoma cancer
- Peritoneal Cancer Index (PCI) score \> 8, or \<=8 and patient not fit for cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (CRS + HIPEC)
- Patients with isolated ovarian metastasis could be included
- White blood cells \>3.5000/mm3; neutrophils \> 1.500/mm3; platelets \>100,000/mm3
- Creatinine \<1.5mg/dL and creatinine clearance \>60ml/min and serum total bilirubin \<2mg/dL
- Ability to give written consent prior to commencement of treatment
排除标准
- Extraperitoneal metastases including liver metastases and malignant pleural effusion. The presence of suspicious retroperitoneal lymph nodes is not an exclusion criterium.
- Patients with adenocarcinoma of Siewart I
- Bowel obstruction, not tolerating oral diet
- HER2+++ tumor with indicated for Trastuzumab therapy
- Any laparotomy during 3 months before inclusion. (Laparoscopy is not an exclusion criterium)
- Contraindicated to any drug contained in the chemotherapy regimen
- Concomitant intraperitoneal chemotherapy, immunotherapy or target therapy
- Active infectious (bacterial, viral) disease. Elevated CRP with no identified focus is not an exclusion criterium
- Pregnancy or breastfeeding
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。